Juventas Therapeutics, Inc. To Present Top-Line Interim Results From Phase II STOP-HF Trial In Late-Breaking Oral Presentation At European Society of Cardiology Heart Failure Congress /PRNewswire-USNewswire/ -- Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a ... (more)
http://ift.tt/1ijnyKl
http://ift.tt/1ijnyKl
No comments:
Post a Comment